A sequentially outcome-adaptive Bayesian design is proposed for choosing the dose of an experimental therapy based on elicited utilities of a bivariate ordinal (toxicity, efficacy) outcome. Subject to posterior acceptability criteria to control the risk of severe toxicity and exclude unpromising doses, patients are randomized adaptively among the doses having posterior mean utilities near the maximum. The utility increment used to define near-optimality is nonincreasing with sample size. The adaptive randomization uses each dose's posterior probability of a set of good outcomes, defined by a lower utility cutoff. Saturated parametric models are assumed for the marginal dose-toxicity and dose-efficacy distributions, allowing the possible requirement of monotonicity in dose, and a copula is used to obtain a joint distribution. Prior means are computed by simulation using elicited outcome probabilities, and prior variances are calibrated to control prior effective sample size and obtain a design with good operating characteristics. The method is illustrated by a Phase I/II trial of radiation therapy for children with brainstem gliomas.
INTRODUCTION
We propose a Bayesian Phase I/II procedure for sequentially adaptive dose selection based on a bivariate ordinal (toxicity, efficacy) outcome. The method is based on elicited utilities of the possible outcome pairs (cf. Berger, 1985) . Rather than choosing the dose that maximizes the posterior mean utility, we deal with the well-known "exploration versus exploitation" dilemma (cf. Sutton and Barto, 1998) by adaptively randomizing patients among the doses having posterior mean utilities that differ from the maximum by less than a specified increment. We require this increment to be nonincreasing with sample size, similarly to an "epsilon-decreasing" version of an "epsilon-greedy" algorithm. The adaptive randomization (AR) uses each dose's posterior probability of a set of good outcomes, defined by an elicited lower utility cutoff. We obtain a bivariate model by first constructing marginals and using a copula (Nelsen, 1999) to induce association. Aside from link functions,
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we do not assume functional forms for dose-toxicity or dose-efficacy curves, but rather use marginals with saturated parameterizations. We establish a prior by using elicited outcome probabilities to simulate many very large pseudo samples, with the mean parameter vector of the pseudo-posteriors used as the prior mean parameter vector, and the prior variances calibrated to control prior effective sample size.
Because we consider bivariate ordinal outcomes, our methodology differs substantively from Phase I/II designs based on trinary or bivariate binary outcomes (cf. Thall and Russell, 1998; O'Quigley et al., 2001; Braun, 2002; Thall and Cook, 2004; Bekele and Shen, 2004; Zhang et al., 2005; Dragalin and Fedorov, 2006; Thall et al., 2008) . Our design may be considered a Phase I/II, utility-based generalization of several Bayesian Phase I methods. Bekele and Thall (2004) use a continual reassessment method (CRM; O'Quigley et al., 1990) type criterion based on posterior means of summed severity scores of multivariate ordinal toxicities; however, their methodology does not incorporate efficacy, maximize a utility, or use AR. For the case of one ordinal toxicity, a method similar to that of Bekele and Thall, but using quasi-likelihood, is proposed by Yuan et al. (2007) , while Van Meter et al. (2011) assume a proportional odds model (McCullagh, 1980) and extend the CRM. Our methodology is similar to the Phase I/II design of Houede et al. (2010) for choosing dose pairs of two agents, with the differences that we incorporate AR, require more complex dose admissibility criteria, and use a model with much weaker assumptions.
In section 2, we describe the motivating trial. The probability model is presented in section 3. Section 4 gives definitions of the utility function, dose admissibility criteria, AR probabilities, and the design. Application to the RT trial is described in section 5, including simulation studies of the method's sensitivity to dose admissibility requirements, the use of AR, maximum sample size, prior variability, and number of doses studied. We close with a discussion in section 6.
A RADIATION THERAPY TRIAL
Diffuse intrinsic pontine gliomas (DIPGs) are aggressive brain tumors for which no treatment with substantive antidisease effect currently exists. DIPGs account for about 75% of brainstem gliomas in children, and the median age of DIPG patients is 5 years. Radiation therapy (RT) is the standard treatment, but nearly all patients experience disease progression within 8 months after RT and median survival is less than 1 year. However, the dose-toxicity and dose-efficacy profiles of RT for this disease are not well understood. This paper was motivated by the desire to design a Phase I/II trial of RT for DIPG patients. The trial, which uses the dose-finding design described here and is ongoing at this writing, includes children with DIPGs who previously received RT with or without chemotherapy and currently have progressive disease. RT is administered by separating a total dose of absorbed radiation (in gray units, Gy) into fractions that are given serially. The biologically equivalent dose is BED = total dose × 1 + d/ , where d = dose/fraction and is a constant corresponding to the type of tissue being irradiated. This model is based on the empirical observation in animal models that the empirical proportion of cells surviving radiation can be fit closely by a linear-quadratic function of per fraction dose (Fowler, 1989) 0  50  25  10  0  1  85  50  15  5  2  92  60  20  7  3  100  75  25  10 Note. The gray-shaded utilities identify the set of "good" outcomes, defined as having utility ≥ 25.
is independent. For brain tissue, = 3, and the three combinations of (total dose, d) to be studied in the DIPG trial are (24, 2.0), (26.4, 2.2), and (30.8, 2.2), so the corresponding BEDs are 40.00, 45.76, and 53.39. Toxicity is defined on a 4-level ordinal scale as low, moderate, high, or severe, with each level defined in terms of fatigue, nausea/vomiting, headache, skin inflammation or desquamation, blindness, and brain edema or necrosis, each evaluated during 42 days from the start of therapy. Efficacy is scored at day 42, and is defined as the sum of three indicators of any improvement, compared to baseline, in (i) clinical symptoms, (ii) radiographic appearance, or (iii) quality of life. Thus, an efficacy score of 0 corresponds to no improvement, 1 to improvement in one of the three categories, and so on.
For our general regime, index the outcomes by k = 1 for toxicity and k = 2 for efficacy, with Y k = 0 1 m k identifying the observed ordinal levels. For toxicity, Y 1 = 0 denotes the least severe and m 1 the most severe level, while Y 2 = 0 denotes the worst and m 2 the best level of efficacy. In the RT trial, m 1 = m 2 = 3. Our proposed dose-finding method requires elicited utilities of all possible values y = y 1 y 2 of the outcome pairs Y = Y 1 Y 2 The elicited utilities U y 1 y 2 for all 16 possible outcomes in the RT trial are given in Table 1 . The RT trial utility has the required property that U y 1 y 2 must increase as either toxicity severity level decreases or efficacy increases. While it may seem counterintuitive that outcomes with efficacy score Y 2 = 0 should be given positive utilities, because the prognosis of the patients in this trial is very poor and treatment is in large part palliative, the oncologists who organized the trial consider achieving a lower level of toxicity to be more desirable for any level of efficacy. When we questioned the oncologists about this critical point during the utility elicitation process, they explained that even when the efficacy outcome score equals 0, there still is some palliative effect, that is, the treatment still is useful. Consequently, when the efficacy score is 0, lower toxicity severity levels are far more desirable, as the first row of Table 1 shows.
PROBABILITY MODELS

Index doses by
by formulating marginals for Y 1 x and Y 2 x and using a copula (Nelsen, 1999) 
m k and k = 1 2. Given a monotone increasing link function g our marginal model assumption is simply
with all
The marginal model (1) is saturated since it has m k parameters for each x with dim k = Jm k which is the number of k y x 's needed to specify the J marginals of Y k for all x Equation (1) ensures that the distribution k y x y = 0 1 m k is well defined for each k and x This follows from the fact that, denoting¯ k y x = Pr Y k ≥ y x k the unconditional and conditional probabilities are related by the recursive formula¯
Consequently,¯ k y x is decreasing in y for each x Jm k -dimensional real-valued k and monotone link g The marginal probabilities are given by
Given the marginals, we obtain a joint distribution of Y 1 Y 2 x by using a bivariate Gaussian copula,
is the bivariate standard normal cdf with correlation , and is the univariate standard normal cdf. This is used to define the joint distribution as
We chose the Gaussian copula for its tractability. Other copulas, such as the Gumbel or Clayton, may be used (Nelsen, 1999) . Denoting the data from the first n patients in the trial, by n = Y 1 x 1 Y n x n , n = 1 N max the likelihood is the product The model parameter vector = 1 2 has dimension p = J m 1 + m 2 + 1 and characterizes a total of J m 1 + m 2 + m 1 m 2 bivariate probabilities. This parameterization is feasible for many cases arising in practice, with J m 1 m 2 = 3 2 2 , 3 3 3 4 3 2 4 3 3 5 2 2 5 3 2 5 3 3 giving corresponding p = 13, 19, 21, 25, 21, 26, 31 . For m 1 = m 2 = 1, which is the bivariate binary outcome case, p = 2J + 1 and k = k 1 k J for k = 1 2 How¯ 1 y x and¯ 2 y x may vary with x depends on both the therapeutic modality and the definitions of toxicity and efficacy. An important case is that where it is necessary to assume that¯ k y x is increasing in x for one or both outcomes. This assumption is appropriate both for cytotoxic agents and for RT, but it may not be realistic for cytostatic or biologic agents. Imposing the constraints k y 1 ≤ k y 2 ≤ · · · ≤ k y J implies that¯ k y x increases in x for each y = 1 m k , due to the monotonicity of g by equation (2). Rather than fitting the model (1) with real-valued k y x 's subject to these constraints, to reduce computation we obtain monotonicity of¯ k y x in x by reparameterizing the model as
with real-valued k y ≡ k y 1 and k y x ≥ 0 for all k, y, and x = 2 J Thus,
and collecting terms we denote = The parameterization (4) borrows strength between doses quite strongly because, for distinct doses x and z k y x , and k y z share many parameters.
The model y x must do a good job of reflecting the way that the posterior mean utility, defined later in section 4.1, changes as a function of dose. Intuitively, it may seem that the number of parameters p in the range 13 to 31 is impractically large for dose-finding trials with small sample sizes. This is not the case, essentially because the information in a bivariate ordinal outcome Y is much greater than that provided by a single ordinal Y or a binary outcome, which is used conventionally in Phase I trials. Since our goal is to find a dose with high mean utility, if the model is tractable then the value of p is not critical. For example, in the case J m 1 m 2 = 5 3 3 where p = 31, the algorithm (section 4.3, later) for computing a prior from elicited values works quite well, implementing the Markov Chain Monte Carlo (MCMC) algorithm for computing posteriors is not problematic, and the design performs well across a large set of different doseoutcome scenarios.
When using a utility U Y to quantify the desirability of a bivariate ordinal patient outcome Y conventional generalized linear models (GLMs; McCullagh and Nelder, 1989) for the marginals may not be sufficiently refined to distinguish reliably between doses. This is especially problematic when a middle dose has the highest utility, which can easily be the case when both¯ 1 y x and¯ 2 y x increase with x The family of GLMs for ordinal Y k given by g ¯ k y x = k y + k x with that g ¯ k y x = k y x which requires that k y x must increase in y for k = 1 2 and all x In the case where¯ k y x must increase in x however, one must impose two sets of monotonicity constraints, one in x and the other in y which limits tractability for adaptive dose-finding. Sensitivity analyses using different marginal distributions showed that, in terms of performance of the dose-finding method, no one model among those described above is uniformly better than the others. However, our simulations (shown later in Table 6 ) showed that, in terms of both dose selection and choosing desirable doses for patients during the trial, the worst performance of the model with saturated marginals was better than the worst performance of the model with proportional odds marginals.
DECISION CRITERIA AND TRIAL DESIGN
Utilities
Denote the elicited utility of outcome y by U y The mean utility of dose x given is
The posterior mean utility is
Note that equation (5) reflects the physicians' utilities and the observed data by averaging over the posterior. We denote the dose that maximizes x n by x opt n Because U y is a patient utility, maximizing x n is very different from the more common Bayesian approach of choosing x to optimize some posterior function of the Fisher information matrix (cf. Haines et al., 2003; Dragalin and Fedorov, 2006) . In the context of Phase I trials, Bartroff and Lai (2010) address the problem of "individual versus collective ethics" by considering an objective function including components for both current and future patients. In our setting, always choosing x opt n based on x n alone is an example of a "greedy algorithm," which in general is a sequentially adaptive decision rule that always takes the locally optimal action at each stage. Motivated by both ethical and practical considerations, we next introduce additional dose acceptability criteria, and an AR procedure, to improve this greedy algorithm.
Dose Acceptability and Adaptive Randomization
Simply maximizing x n ignores the undesirable but important possibility that all doses are too toxic. To control the risk of toxicity, we elicit the level y * of toxicity considered to be unacceptable by the physicians, and an accompanying fixed limit * 1 on the probability¯ 1 y * x of toxicity at or above y * We say that a dose x is unacceptably toxic if where p U is an upper probability cutoff, usually in the range .80 to .95. In the simplest case where Y 1 is a binary indicator of toxicity at or above some specified severity level, so that y = 0 or 1 denote the absence or presence of toxicity defined in this way, y * = 1 by default. The inequality (6) says that x has a high posterior probability of producing an unacceptably high level of toxicity. We will limit all dose assignments to the set of acceptably safe doses, safe n defined to be all x ∈ for which (6) is not the case. This is similar in spirit to the safety requirements used by Thall and Cook (2004) and Braun et al. (2007) , and "escalation with overdose control" proposed by Babb et al. (1998) for Phase I trials.
A very important practical problem when using x n to select doses adaptively is that, in some cases, little or no information may be obtained for the dose that actually has the highest true mean utility, u x true . This occurs when the algorithm that chooses x by maximizing x n repeatedly assigns a dose that actually is suboptimal, and does not escalate to higher levels that include the true optimal dose. The general phenomenon of a greedy sequential decision procedure becoming stuck at a suboptimal treatment is well known. A common solution for this problem is to randomly assign some patients to suboptimal treatments. This distributes patients more evenly among treatments and consequently more is learned about the design space, often with a resulting improvement in the method's reliability. To do this in an ethical way for adaptive dose-finding, we use the following constrained AR procedure.
Let n n = 1 N max be a nonincreasing sequence of differences in the utility domain. We define the set of n -optimal doses to be
This is the set of doses having posterior mean utility within n of the maximum value. The sequence n quantifies what is meant by posterior mean utilities being "close" in expression (7), and we require it to be nonincreasing with n to accommodate the decreasing variability in the posteriors of the u x 's as n increases. Restriction of the AR to doses in n is motivated by both ethical considerations and the practical fact that the posteriors of the utilities u x x ∈ safe n may be quite disperse, especially for the small values of n in a dosefinding trial. Moreover, x n may be nearly flat around its maximum, with the numerical superiority of x opt n n over x n for one or more x = x opt n quite small. Our simulations, summarized later in section 5, show that it sometimes is more ethical to treat some patients at suboptimal doses having x n near x opt n n because on average, in many scenarios, this leads to more patients in the trial being treated at doses having higher utilities.
A third acceptability criterion that may be used is to require that a dose should not be unlikely to have the highest utility. We say that a dose x is unlikely to be best if
for a small lower probability cutoff p L . We denote the set of doses that do not have this property by minimality requirement that it has at least a nontrivial probability of having the highest utility. Combining the three criteria (6), (7), and (8), we define the set of acceptable doses to be
Thus, a dose is acceptable if it (i) has acceptable toxicity, (ii) has posterior mean utility that is n -close to the maximum, and (iii) is not unlikely to have the highest posterior utility.
Our design randomizes patients adaptively among the doses in n This may be done using many different criteria. An ethically attractive approach is to define AR probabilities in terms of a set of "good" outcomes, defined as G = y U y ≥ U where the lower limit U is elicited from the physicians who provided the utilities. Given G the probability of a good outcome for a patient treated with dose x is Pr Y ∈ G x
Denoting the posterior means G x n = E Pr Y ∈ G x n we randomize a patient to dose x ∈ n with probability r x n = G x n z∈ n G z n (10) Thus, the dose-finding method includes the requirements that it only assigns doses that are safe and n -optimal, as defined by (6) and (7), and that satisfy the minimality requirement (8), and it uses the good outcome set G to determine the AR probabilities (10).
Establishing a Prior
Denote the normal distribution with mean and variance 2 by N 2 and denote the normal distribution truncated below at 0 by N 0 2 For the prior p ˜ , we assume k y ∼ N ˜ k y ˜ 2 k y ) and k y x ∼ N 0 ˜ k y x ˜ 2 k y x ). The numerical values of the hyperparameters˜ = ˜ ˜ ˜ 2 ˜ 2 may be established from elicited probabilities using the following algorithm, similar to that given inciteTet11.
Step 1. Assume a noninformative pseudo-prior on with all entries N 0 2 o for large 2 o
Step 2. Use the elicited prior probabilities to simulate a large pseudo-sample of size N balanced equally among the doses.
Step 3. Compute the pseudo-posterior from the pseudo-prior and pseudosample, and record the pseudo-posterior mean.
Step 4. Repeat steps 2 and 3 M times, and set the prior mean ˜ ˜ of equal to the mean of the M pseudo-posterior means.
Step 5. Using the effective sample size (ESS) as a criterion, calibrate the values of ˜ 2 ˜ 2 to obtain ESS values of the k y x 's in the range 0.20 to 1.0.
As a practical guideline, this algorithm may be applied effectively with N = 100 J , that is; 100 observations per dose, M = 1000 pseudo-samples, and Downloaded by [ alternatively, one may approximate the prior of each k y x as a beta(a b), set its ESS equal to a + b and average these values to obtain a single summary ESS. For the association parameter in the Gaussian copula, a uniform prior on −1 +1 may be assumed.
Trial Conduct
The trial is conducted as follows. An initial cohort is treated at a starting dose chosen by the physicians. For all subsequent cohorts, once the posterior is updated based on the observed outcomes of previous patients, if n is empty then the trial is stopped and no dose is chosen; otherwise, patients are randomized among the doses in n using the updated AR probabilities given by (10). A rule superseding the preceding is that no untried dose may be skipped when escalating. At the end of the trial, if n is not empty, x opt N max is selected. To summarize, the design requires the following quantities to be elicited from the physicians: the prior means of all k y x 's, the utilities, the cutoff U that determines G, the safety parameters y * and * 1 a starting dose, and the number of patients treated at the starting dose. Given this information, prior parameters must be determined from the elicited values, for example, by using the simulation-based approach described earlier, and the additional design parameters p U p L n N max and cohort size must be specified. These parameters, along with prior variances, should be calibrated by simulating the trial to obtain good operating characteristics.
APPLICATION TO THE RADIATION THERAPY TRIAL
Trial Design
For the RT trial, since m 1 = m 2 = 3, the distribution k y x y 1 y 2 = 0 1 2 3 is determined by 15 probabilities for each x Since J = 3, there are J m 1 m 2 + m 1 + m 2 = 45 bivariate probabilities. For each k and x, the marginals (3) are given by
We assume a logit link, so k y x = e k y x / 1 + e k y x For each k = 1 2 and y = 1 2 3 k y = k y k y 2 k y 3 so dim k = 9 and p = dim The prior was obtained from the elicited prior mean probabilities in Table 2 using the algorithm described in section 4.3. We simulated 1000 pseudo-samples, each of size 300, with 100 patients in each pseudo-sample assigned to each dose. For each simulated data set, a pseudo-posterior was computed starting with a pseudoprior on with each k y x ∼ N 0 60 2 , and the mean of the 1000 pseudo-posterior means was used as the prior means˜ k y and˜ k y x The standard deviations of the k y x 's were calibrated by approximating the prior of each k x y with a beta a b and using ESS = a + b Setting all˜ k y =˜ k y x =˜ = 6 gave ESS values ranging from 0 31 to 0 70 with mean ESS = 0 42.
For the safety criterion, safe n the physicians specified y * = 3 (severe toxicity) and * 1 = 0 10. Using the conservative upper cutoff p U = 0 80, a dose x is unacceptably toxic if Pr 1 x 3 ≥ 10 n > 80 The lower cutoff p L = 0 10 was used to define min n after studying effects of the values p L = 0 05, 0.10, 0.15 in preliminary simulations. An initial cohort of 3 patients will be treated at x = 1 (BED = 40 00), with subsequent cohorts of size 1 and the AR started at the 4th patient. A maximum of N max = 30 patients will be treated, chosen in part because an accrual rate of 6 to 10 patients per year is anticipated, so it will require 3 to 5 years to complete the trial. The physicians specified the lower utility U = 25 to determine the good outcome set, which is used to define the AR probabilities. The nine outcomes considered to be good by this criterion are shown by the gray shaded values in Table 1 . After a preliminary sensitivity analysis examining the design's behavior by simulation for various sequences n including 10 ≤ n ≤ 30 and several non-decreasing functions, it was decided to use the step function n = 20 for 4 ≤ n ≤ 15 and n = 15 for 16 ≤ n ≤ 30 to define n All posterior quantities were computed using MCMC with Gibbs sampling (Robert and Cassella, 1999) . All simulations are based on 5000 iterations of each case studied.
Simulation Results
Using this design, we simulated the trial under eight scenarios, each determined by a set of assumed true probabilities, true k y x given in Fig 1. Scenario 1 is based on the elicited prior means, which give equal utility 64.6 to x = 1 and 2 and utility 57.0 to x = 3. Scenario 2 has steeply increasing utility with x = 3 best. Scenario 3 has steeply decreasing utility with x = 1 best, the middle dose x = 2 is best in Scenario 4, and the utility is V-shaped in Scenario 5 with x = 3 best. No dose is acceptably safe in Scenario 6. Scenario 7 is similar to Scenario 4 in terms of utilities, but has slightly higher toxicity and efficacy probabilities. The utility Note. The assumed true marginal probabilities true k y x defining each scenario are given in Fig. 1 . Under each scenario, each tabled dose selection percentage and each sample size are the mean from 5000 simulated trials. "None" means that no dose was selected.
is V-shaped in Scenario 8 with x = 1 best. In each simulation scenario, the true marginal probabilities true k y x do not depend on the assumed model, although we use the copula to determine correlations. The Gaussian copula correlation parameter true = 0 10 was used throughout. The true utilities u true x are determined by the assumed true k y x , true and the elicited utilities U y in Table 1 . The results of simulating the RT trial design under Scenarios 1-8 are summarized in Table 3 . In Scenario 6, where no dose is acceptably safe and the true severe toxicity probabilities are 0.25, 0.28, 0.30 at the three doses, the method correctly stops early and chooses no dose 91% of the time, and treats on average 14.6 patients. Modifying Scenario 6 so that the true severe toxicity probabilities at the three doses are the slightly higher values .30, .35, .40, the stopping probability is 98% and the mean sample size drops to 11.6 patients. In all of the other seven scenarios, the selection probabilities reflect the utilities quite closely. The algorithm's selection reliability is quite striking in Scenarios 5 and 8, which have V-shaped utilities with the middle dose x = 2 least desirable. The sample size distributions are biased toward lower doses in all scenarios, reflecting the initial cohort of 3 patients at x = 1, the do-not-skip rule, and the fact that the prior was biased toward the lower doses, which favors AR to these doses early in the trial.
While Table 3 shows that our method has very desirable properties for the RT trial design, since it relies on three particular admissibility criteria and AR, it is important to assess each design component's effect on the method's performance. We thus simulated four alternative versions of the procedure. Method 1 is our proposed procedure with n given by (9). Method 2 drops the minimality requirement to the optimum. Thus, Methods 1, 2, and 3 all use AR based on the posterior probabilities r x n of a good outcome, but with different definitions of an acceptable dose. Method 4 drops the AR entirely, and uses the greedy algorithm that simply chooses x to maximize x n subject only to the safety constraint on toxicity. Thus, n = safe n for both Methods 3 and 4, but Method 4 does not use AR. The results of this additional comparative simulation are given in in Table 4 . To present the results in a more compact way than giving four versions of Table 2 , one for each version of the method, instead we use the following two summary statistics to quantify each method's performance. For each scenario, let u true x select denote the true utility of the final selected dose, and u max and u min the largest and smallest possible true utilities among all x ∈ A statistic that quantifies how well the method selects a final dose for future patients is
the proportion of the difference between the utilities of the best and worst possible choices that is achieved by x select A similar statistic that quantifies how well the method assigns doses to patients throughout the trial is
where u true x i is the true utility of the dose given to the ith patient, and N is the achieved final sample size. Both statistics have range 0 1 , with a larger value corresponding to better overall performance. Thus, R select quantifies future patient benefit while R treat quantifies the benefit to the patients in the trial.
To interpret the results in Table 4 , we first note that all four methods are safe in that they stop and select no dose between 90% and 93% of the time in the Note. Method 1 is the proposed procedure. Methods 2, 3, and 4 successively drop the minimality requirement x ∈ min n the n -close requirement x ∈ n and the use of adaptive randomization (AR). The numbers in parentheses after R select are the percentages of the trial being stopped with no dose selected.
toxic Scenario 6. This is as expected, since all of the methods include the safety requirement (6). For the other seven scenarios, Table 4 shows that Method 4, the greedy algorithm with the safety requirement but no AR, may perform either extremely well (in Scenarios 1, 3, and 8), moderately well (in Scenarios 4 and 5), or extremely poorly (in Scenarios 2 and 7). That is, Method 4 is inconsistent and sometimes yields disastrous results. In particular, Method 4 gives the extremely small values R treat = 0 10 in Scenario 2 and R treat = 0 20 in Scenario 7, compared to much larger values for Methods 1-3. Thus, depending on the actual state of nature, the greedy algorithm without AR may perform either very well or very poorly in terms of benefit to the patients in the trial. In contrast, across all scenarios considered Methods 1-3 are all much more reliable, with no scenarios where any of these methods have extremely poor performance. Thus, the addition of AR acts like an insurance policy against disaster, but with the price being reduced performance in terms of R select and R treat in some cases. Comparing Methods 1, 2, and 3, the greatest effect of adding the admissibility constraints n and min n is that they both increase R treat substantially in almost all scenarios. Thus, these two dose admissibility constraints have the effect of making the dose-finding algorithm more ethically attractive for the patients in the trial. In contrast, in terms of future patient benefit, Table 4 shows that most of the advantage over Method 4 in Scenarios 2, 4, 5, and 7 is due to including AR, since the R select values for Methods 1, 2, and 3 are about the same in these scenarios.
Our motivating application is somewhat atypical in that most Phase I/II trials have more than three dose levels. To more fully illustrate the methodology, we also include a simulation study with J = 5 doses. The model, which now has p = 31 parameters, and the design used for this simulation are very similar to those of the RT trial, but we assume N max = 40. With regard to choice of N max in practice, it should be kept in mind that a Phase I/II trial replaces the more conventional approach of conducting Phase I based on toxicity only and Phase II based on efficacy only. Thus, N max = 40 is quite reasonable for a Phase I/II trial. All numerical values in the prior and model corresponding to the new doses x ∈ 1 2 3 4 5 were obtained by matching values for x = 1 3 5 to x = 1 2 3 respectively, and interpolating to obtain values for x = 2 and x = 4. This simulation is summarized in Table 5 , which shows that the qualitative behavior of the design for J = 5 dose levels is very similar to what is shown for J = 3 in Table 3. A natural question is, how well does the method work using a more conventional model with fewer parameters? To answer this, we also simulated the trial assuming a bivariate model with PO marginals defined by logit ¯ k y x = k y + k x with k 1 > k 2 > k 3 so = 1 1 1 2 1 3 2 1 2 2 2 3 1 2 ) and p = 9. The prior for this model was obtained similarly to that of the 19-parameter model, using the method described in section 4.3. The results are summarized in Table 6 , which shows that the simpler model gives a design with greatly inferior performance in Scenarios 1, 4, 6, and 7, superior performance in Scenarios 2 and 5, and the comparative results are mixed in Scenarios 3 and 8. This illustrates the point that, in the present setting, no model is uniformly best. Note. The numbers in parentheses after R select are the percentages of the trial being stopped with no dose selected. performs much more consistently across a diverse set of scenarios, with far better worst-case results than the simple model.
DISCUSSION
In our proposed design, we have modified the approach of maximizing the posterior mean utility by imposing several dose acceptability criteria and using AR among near-optimal doses. As shown in Table 4 , each modification improved the method's performance, in terms of both reliability and ethical desirability. While it may seem counterintuitive, in some scenarios randomizing patients to interimly suboptimal doses actually increases the average utility of the doses assigned to patients throughout the trial. We also found that using a model with saturated marginals gives a design with more consistent overall performance compared to a model with conventional proportional odds marginals.
Several questions remain, and are areas for future investigation. In principle, the utility function might be generalized to include information, monetary costs, or a future patient horizon. Since these utilities have qualitatively different ranges, combining them to actually conduct a trial is a difficult practical and ethical problem (cf. Dragalin and Fedorov, 2006; Bartroff and Lai, 2010) . Other issues include the use of bivariate event times as outcomes (cf. Yuan and Yin, 2009) , and addressing the more general problems of optimizing a two-agent combination or both dose and schedule (Braun et al., 2007) .
